May 16 (Reuters) - Theratechnologies Inc
* Decided to withdraw marketing authorization application
for registration of 2 mg/vial presentation of tesamorelin in
Brazil
* Co and its partner are currently evaluating required steps
to seek and obtain approval of 1 mg/vial presentation
* Decision by co, Sanofi (PA:SASY) based on receipt of questions
asked by regulatory authority, ANVISA
* Decision by co, Sanofi also based on , fact that
presentation is no longer available in any other territory
Source text for Eikon: ID:nMKWPq0Qza
Further company coverage: TH.TO
(Bengaluru Newsroom: +1 646 223 8780)